Transcode Therapeutics Inc (RNAZ) — Cash Flow-to-Debt Ratio
Transcode Therapeutics Inc (RNAZ) has a Cash Flow-to-Debt Ratio of -393.72x as of March 2026, meaning its operating cash flow of $-4.98 Billion could theoretically repay -394% of its total liabilities ($12.64 Million) in one year. See Transcode Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Transcode Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Transcode Therapeutics Inc across 8 annual periods. For the full cash flow conversion analysis, see Transcode Therapeutics Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Transcode Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for Transcode Therapeutics Inc. Check cash flow quality index of Transcode Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | $-19.52 Million | $152.06 Million | ▲ +91.0% |
| 2024 | -1.43x | $-13.34 Million | $9.31 Million | ▲ +72.0% |
| 2023 | -5.12x | $-18.07 Million | $3.53 Million | ▼ -41.3% |
| 2022 | -3.63x | $-15.76 Million | $4.35 Million | ▼ -74.5% |
| 2021 | -2.08x | $-5.27 Million | $2.53 Million | ▼ -1781.9% |
| 2020 | -0.11x | $-492.97K | $4.46 Million | ▲ +71.5% |
| 2019 | -0.39x | $-508.51K | $1.31 Million | ▲ +7.2% |
| 2018 | -0.42x | $-299.57K | $718.61K | — |